LNC1010 / LNC1014
Neuroendocrine Tumors
Key Facts
About Lantheus Holdings
Lantheus Holdings is a commercial leader in the radiopharmaceutical space, built on a vertically integrated model spanning discovery through global sales. Its strategy is anchored by the commercial success of PYLARIFY®, a leading PSMA PET imaging agent for prostate cancer, and DEFINITY®, an established ultrasound contrast agent. The company is advancing a deep pipeline of approximately 40 programs, targeting expansion in radiopharmaceutical oncology and diagnostics, while leveraging its robust manufacturing and commercial infrastructure to drive growth. With a market cap of ~$4.8B, Lantheus is positioned as a key consolidator and innovator in the high-growth targeted radiopharmaceutical sector.
View full company profileTherapeutic Areas
Other Neuroendocrine Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology Focus (Neuroendocrine Tumors) | Curium Pharma | Not Specified |
| Lutathera® | Novartis | Approved / Phase III |
| Zanzalintinib (XL092) | Exelixis | Phase 3 |
| CRN01941 | Crinetics Pharmaceuticals | Phase 1 |